Papageorgiou SG, et al. - Given that the demethylating factor 5-azacytidine (5-AZA) improves survival in intermediate-2 and high risk MDS patients (according to the International Prognostic Score System [IPSS]) responding to treatment, researchers intended to explore the outcome of patients achieving stable disease (SD) in this retrospective study of the Hellenic MDS Study Group. Study participants were 353 intermediate-2 or high IPSS-risk patients treated with 5-AZA. The findings from the present study suggested that MDS patients achieving SD in the initial six months of treatment with AZA should continue receiving AZA, since they might benefit from prolonged treatment.